⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study of Oncological Outcomes of D3 Lymph Node Dissection in Colon Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of Oncological Outcomes of D3 Lymph Node Dissection in Colon Cancer

Official Title: Study of Oncological Outcomes of D3 Lymph Node Dissection in Colon Cancer

Study ID: NCT03009227

Study Description

Brief Summary: The purpose of this study is to determine wether D3 lymph node dissection gives superior oncological outcomes compared to standard D2 lymph node dissection in colon cancer

Detailed Description: The design involves random allocation of eligible patients to D3 or D2 lymph node dissection group in 1:1 ratio. The extent of colonic resection itself is not influenced by the randomization and is predefined by the investigator prior to randomization. Requirements applied to centers participating in the trial and surgeons performing procedures are described in the protocol and refer to center volume and surgeon's experience with evaluation of non-edited video-recordings of procedures. Routine quality control includes requirement to photograph vessels with the clip to determine the extent of lymph node dissection performed and a thorough morphological assessment of the specimen. After surgery patients are treated according to local standards with no difference wether D2 or D3 lymph node dissection was performed. Short-term and long-term outcomes are registered as per protocol. This is a superiority trial evaluating statistical superiority. With the 50% five year survival according to national registry for colon cancer, expecting 10% improvement in survival with D3 lymph node dissection, enrollment of 768 patients during 3 year accrual period followed by 5 year follow up is required for a power of 80%. The intent-to-treat principle is used for the data analysis.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Krasnodar City clinical hospital #1, Krasnodar, , Russian Federation

State Scientific Centre of Coloproctology, Moscow, , Russian Federation

Moscow city oncological hospital #62, Moscow, , Russian Federation

P. Herzen Moscow Oncology Research Institute, Moscow, , Russian Federation

Medical radiological scientific center named after A.F. Tsyba, Obninsk, , Russian Federation

Rostov Research Institute of Oncology, Rostov, , Russian Federation

St Petersburg City Clinical Oncology Dispensary, Saint Petersburg, , Russian Federation

Saint-Petersburg Clinical Research center of specialized kinds of medical care (Oncology), Saint Petersburg, , Russian Federation

Scientific-Research institute of Oncology named after N.N. Petrov, Saint Petersburg, , Russian Federation

Saint-Petersburg State University Clinic, Saint Petersburg, , Russian Federation

Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, , Russian Federation

Republican clinical oncological dispencery, Ufa, , Russian Federation

Contact Details

Name: Aleksei Karachun, Ph.D.

Affiliation: N.N. Petrov Research Institute of Oncology, Surgical department of abdominal oncology, St. Petersburg, Russian Federation

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: